CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.29
+6.13%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.30
From 52W high−73.68%
Volume88461.00
Market cap$46.28M
P/E (TTM)—
P/S (TTM)234.9x
Div yield—
Key dataOct 19, 2026
Open
$3.30
From 52W high
−73.68%
Volume
88461.00
Market cap
$46.28M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
34.7
MomentumView details →
1D Return
+6.13%
YTD Return
−43.87%
SummaryUpdated Jun 1, 2026
Clene Inc. (NASDAQ:CLNN) is a clinical-stage pharmaceutical company founded in 2013 and headquartered in Salt Lake City, Utah. The company went public in October 2018 and focuses on developing novel nanotechnology-based therapeutics for treating neurodegenerative diseases. Clene specializes in clean-surfaced nanotechnology (CSN) therapeutics, with its lead drug candidate CNM-Au8 currently in multiple clinical trials for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson's disease. The company operates in the biotechnology sector within the broader healthcare industry.
Similar companies
Latest newsMore news →
Clene Inc. submitted a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis.12h agoClene completed a $4 million registered direct offering, extending its cash runway beyond the FDA's decision on the CNM-Au8 new drug application.29d agoClene Inc. priced a $4 million registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, including insiders.34d ago